Wave expects to initiate a Phase 2a multidose portion of WVE-007 INLIGHT clinical trial in individuals living with obesity ...

Initial AX-0810 data show no safety signals after 4 weeks of dosing and pharmacokinetics consistent with non-clinical data; ...

Adenosine deaminase acting on RNA (ADAR) is the enzyme responsible for adenosine-to-inosine (A-to-I) RNA editing, a process ...

New research led by Joshua Rosenthal, PhD, of the Marine Biological Laboratory (MBL) and Eli Eisenberg, PhD, at Tel Aviv University, has revealed that octopuses and their close relatives adjust to ...

Ascidian Therapeutics ("Ascidian"), a biotechnology company seeking to treat human diseases by rewriting RNA, and Forge ...

Maddy has a degree in biochemistry from the University of York and specializes in reporting on health, medicine, and genetics. Maddy has a degree in biochemistry from the University of York and ...

ProQR Therapeutics is advancing its Axiomer ADAR-mediated RNA editing pipeline, aiming to file a Clinical Trial Application for its lead program AX-0810, targeting NTCP for cholestatic diseases, by Q2 ...

In a paper published on aBIOTECH, the authors investigated the off-target effects of ADAR-mediated RNA editing in rice ...

New research provides a mechanistic map of how genetic mutations disrupt RNA splicing in acute myeloid leukemia.